Sigyn Therapeutics, Inc.
SIGY
$2.75
$0.2610.44%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.18% | -23.42% | 40.86% | 2.11% | 6.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.32% | -33.35% | 25.78% | 5.02% | 20.85% |
| Operating Income | 13.32% | 33.35% | -25.78% | -5.02% | -20.85% |
| Income Before Tax | 11.81% | 55.55% | -32.15% | -19.26% | 43.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.81% | 55.55% | -32.15% | -19.26% | 43.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.81% | 55.55% | -32.15% | -19.26% | 43.47% |
| EBIT | 13.32% | 33.35% | -25.78% | -5.02% | -20.85% |
| EBITDA | 13.32% | 33.20% | -25.89% | -5.25% | -21.17% |
| EPS Basic | 32.41% | 65.12% | -15.19% | -4.34% | 55.81% |
| Normalized Basic EPS | 32.41% | 71.18% | -15.18% | 19.01% | 56.33% |
| EPS Diluted | 32.26% | 64.73% | -15.05% | -4.48% | 55.54% |
| Normalized Diluted EPS | 32.41% | 71.18% | -15.18% | 19.01% | 56.33% |
| Average Basic Shares Outstanding | 30.48% | 27.46% | 14.74% | 14.29% | 27.95% |
| Average Diluted Shares Outstanding | 30.48% | 27.46% | 14.74% | 14.29% | 27.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |